Platelets and Endothelial Cells Act in Concert to Delay Thrombolysis – Evidence from an In Vitro Model of the Human Occlusive Thrombus

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Thrombosis and Haemostasis

• Publication date

  1998-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0037-1614953PMID 9531049
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Calcium-dependent Stabilization of Type I Plasminogen Activator Inhibitor within Plateletα-Granules (*)

  1996cited by this paper
• Plasminogen activator inhibitor-1 secretion of endothelial cells increases fibrinolytic resistance of an in vitro fibrin clot: evidence for a key role of endothelial cells in thrombolytic resistance.

  1996cited by this paper
• The significance of fibrin binding by plasminogen activator inhibitor 1 for the mechanism of tissue-type plasminogen activator-mediated fibrinolysis

  1995cited by this paper
• Molecular evolution of plasminogen activator inhibitor‐1 functional stability.

  1995cited by this paper
• Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop.

  1994cited by this paper
• Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction.

  1994cited by this paper
• The specific roles of finger and kringle 2 domains of tissue-type plasminogen activator during in vitro fibrinolysis.

  1994cited by this paper
• Transport Phenomena and Clot Dissolving Therapy: An Experimental Investigation of Diffusion-Controlled and Permeation-Enhanced Fibrinolysis

  1994cited by this paper
• Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.

  1994cited by this paper
• Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface.

  1994cited by this paper
• A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction.

  1994cited by this paper
• Flow through clots determines the rate and pattern of fibrinolysis.

  1994cited by this paper
• Structure-function Studies of the t-PA Molecule

  1993cited by this paper
• The Roles of α2-Antiplasmin and Plasminogen Activator Inhibitor 1 (PAI-1) in the Inhibition of Clot Lysis

  1993cited by this paper
• On the future of thrombolytic therapy for acute myocardial infarction.

  1993cited by this paper
• Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus.

  1993cited by this paper
• Thrombolysis in acute myocardial infarction.

  1993cited by this paper
• An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.

  1993cited by this paper
• Statistical analysis of drug combinations for synergism.

  1992cited by this paper
• Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction.

  1992cited by this paper
• Plasminogen Activator Inhibitor Type 1: Biochemistry and Evidence for Modulation of Fibrinolysis In Vivo

  1992cited by this paper
• Thrombolysis in acute myocardial infarction.

  1992cited by this paper
• Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS)

  1992cited by this paper
• Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution.

  1992cited by this paper
• Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction. RAAMI Study Investigators.

  1992cited by this paper
• Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction.

  1992cited by this paper
• Evidence that postoperative fibrinolytic shutdown is mediated by plasma factors that stimulate endothelial cell type I plasminogen activator inhibitor biosynthesis.

  1992cited by this paper
• Inhibition of Plasminogen Activator Inhibitor‐1 Activity Results in Promotion of Endogenous Thrombolysis and Inhibition of Thrombus Extension in Models of Experimental Thrombosis

  1992cited by this paper
• Lysis of Platelet‐rich Thrombi: The Role of PAI–1 a

  1992cited by this paper
• Inhibition of Platelet Adhesion to Fibrin(ogen) in Flowing Whole Blood by Arg-Gly-Asp and Fibrinogen γ-Chain Carboxy Terminal Peptides

  1992cited by this paper
• Integrins in thrombosis, wound healing and cancer.

  1991cited by this paper
• High resolution analysis of functional determinants on human tissue-type plasminogen activator.

  1991cited by this paper
• On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator.

  1991cited by this paper
• The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance.

  1991cited by this paper
• Platelets stimulate endothelial cells to synthesize type 1 plasminogen activator inhibitor. Evaluation of the role of transforming growth factor beta.

  1991cited by this paper
• Induction of plasminogen activator inhibitor by products released from platelets.

  1990cited by this paper
• The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator.

  1990cited by this paper
• Endothelial cell fibrinolytic assembly.

  1990cited by this paper
• The Fibrinolytic System of the Vessel Wall and Its Role in the Control of Thrombosis

  1990cited by this paper
• von Willebrand factor competes with fibrin for occupancy of GPIIb:IIIa on thrombin-stimulated platelets.

  1990cited by this paper
• von Willebrand factor competes with fibrin for occupancy of GPIIb:IIIa on thrombin-stimulated platelets

  1990cited by this paper
• Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells.

  1989cited by this paper
• Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.

  1989cited by this paper
• Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator.

  1989cited by this paper
• Identification of the domains of tissue-type plasminogen activator involved in the augmented binding to fibrin after limited digestion with plasmin.

  1989cited by this paper
• What is synergy?

  1989cited by this paper
• Update: thrombolysis.

  1989cited by this paper
• What is synergy?

  1989cited by this paper
• Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase

  1988cited by this paper
• Plasminogen activator inhibitor (PAI‐1) in plasma and platelets

  1988influential reference
• Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation.

  1987cited by this paper
• Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

  1987cited by this paper
• Fibrin assembly. Lateral aggregation and the role of the two pairs of fibrinopeptides.

  1986cited by this paper
• The fibrinolytic system in man.

  1986cited by this paper
• Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activator by the fast-acting inhibitor of plasminogen activator in vitro and in vivo.

  1986cited by this paper
• The expected effect of a combination of agents: the general solution.

  1985cited by this paper
• Reverse fibrin autography: a method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate--polyacrylamide gel electrophoresis.

  1984cited by this paper
• A study of the kinetics of ADP-triggered platelet shape change.

  1984cited by this paper
• Detection and partial characterization of an inhibitor of plasminogen activator in human platelets.

  1984cited by this paper
• FIBRIN ASSEMBLY *

  1983cited by this paper
• Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.

  1982cited by this paper
• Assembly of fibrin. A light scattering study.

  1979cited by this paper
• Comparative studies of the fibrinolytic activity of cultured vascular cells.

  1979cited by this paper
• Mass–length ratio of fibrin fibers from gel permeation and light scattering

  1977cited by this paper
• Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria.

  1973cited by this paper

• Neutrophil extracellular traps contribute to tissue plasminogen activator resistance in acute ischemic stroke

  2021cites this paper
• Heparin, coumarin, protein C, antithrombin, fibrinolysis and other clotting related resistances: old and new concepts in blood coagulation

  2017cites this paper
• Pathological features of intracardiac bacterial vegetation and intracranial arterial thrombus due to infective endocarditis in a stroke patient.

  2014cites this paper
• Endothelial Cells Organize Fibrin Clots into Structures That Are More Resistant to Lysis

  2004cites this paper
• Key References: Basic Fibrinolysis and Thrombolysis Selected References: 1987–1997

  2004cites this paper
• Endothelial inflammation and thrombolysis resistance in acute myocardial infarction.

  2002cites this paper
• Coagulation and Fibrinolysis in Diabetes

  2002cites this paper
• Regulation of PAI-1 Concentration in Platelets by Systemic Administration of Antisense Oligonucleotides to Rats

  2001cites this paper